Corinne Jenkins
Stock Analyst at Goldman Sachs
(1.74)
# 3,075
Out of 4,874 analysts
62
Total ratings
44.19%
Success rate
-3.27%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Corinne Jenkins
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $59 → $66 | $61.58 | +7.18% | 8 | Dec 5, 2024 | |
| TGTX TG Therapeutics | Maintains: Neutral | $20 → $22 | $37.95 | -42.03% | 8 | Nov 5, 2024 | |
| FULC Fulcrum Therapeutics | Upgrades: Buy | $6 → $15 | $7.38 | +103.25% | 2 | May 14, 2024 | |
| IDYA IDEAYA Biosciences | Maintains: Buy | $53 → $46 | $22.29 | +106.37% | 5 | May 13, 2024 | |
| ROIV Roivant Sciences | Maintains: Buy | $16 → $18 | $11.60 | +55.17% | 5 | Apr 3, 2024 | |
| GERN Geron | Maintains: Buy | $4 → $5 | $1.53 | +226.80% | 3 | Mar 15, 2024 | |
| ALT Altimmune | Reinstates: Neutral | $13 | $3.61 | +260.11% | 3 | Jan 24, 2024 | |
| HRMY Harmony Biosciences Holdings | Maintains: Sell | $25 → $28 | $31.86 | -12.12% | 7 | Jan 9, 2024 | |
| SWTX SpringWorks Therapeutics | Maintains: Buy | $47 → $52 | $46.99 | +10.66% | 5 | Nov 29, 2023 | |
| BTAI BioXcel Therapeutics | Maintains: Neutral | $192 → $64 | $2.03 | +3,052.71% | 6 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $216 → $184 | $9.73 | +1,791.06% | 2 | Mar 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $21 | $1.56 | +1,246.15% | 2 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $14 | $4.00 | +250.00% | 2 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $8 | $29.64 | -73.01% | 2 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $16 | $0.30 | +5,180.53% | 2 | Dec 15, 2021 |
Rhythm Pharmaceuticals
Dec 5, 2024
Maintains: Buy
Price Target: $59 → $66
Current: $61.58
Upside: +7.18%
TG Therapeutics
Nov 5, 2024
Maintains: Neutral
Price Target: $20 → $22
Current: $37.95
Upside: -42.03%
Fulcrum Therapeutics
May 14, 2024
Upgrades: Buy
Price Target: $6 → $15
Current: $7.38
Upside: +103.25%
IDEAYA Biosciences
May 13, 2024
Maintains: Buy
Price Target: $53 → $46
Current: $22.29
Upside: +106.37%
Roivant Sciences
Apr 3, 2024
Maintains: Buy
Price Target: $16 → $18
Current: $11.60
Upside: +55.17%
Geron
Mar 15, 2024
Maintains: Buy
Price Target: $4 → $5
Current: $1.53
Upside: +226.80%
Altimmune
Jan 24, 2024
Reinstates: Neutral
Price Target: $13
Current: $3.61
Upside: +260.11%
Harmony Biosciences Holdings
Jan 9, 2024
Maintains: Sell
Price Target: $25 → $28
Current: $31.86
Upside: -12.12%
SpringWorks Therapeutics
Nov 29, 2023
Maintains: Buy
Price Target: $47 → $52
Current: $46.99
Upside: +10.66%
BioXcel Therapeutics
Aug 15, 2023
Maintains: Neutral
Price Target: $192 → $64
Current: $2.03
Upside: +3,052.71%
Mar 15, 2023
Maintains: Buy
Price Target: $216 → $184
Current: $9.73
Upside: +1,791.06%
Mar 7, 2023
Maintains: Buy
Price Target: $25 → $21
Current: $1.56
Upside: +1,246.15%
Dec 20, 2022
Maintains: Buy
Price Target: $9 → $14
Current: $4.00
Upside: +250.00%
May 24, 2022
Maintains: Neutral
Price Target: $9 → $8
Current: $29.64
Upside: -73.01%
Dec 15, 2021
Initiates: Neutral
Price Target: $16
Current: $0.30
Upside: +5,180.53%